Document is current

Any future updates will be listed below

Sintilimab in combination with stereotactic body radiotherapy and granulocyte-macrophage colony-stimulating factor in metastatic non-small cell lung cancer: The multicenter SWORD phase 2 trial

Crossref DOI link: https://doi.org/10.1038/s41467-024-51807-7

Published Online: 2024-08-22

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark